

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Tixagevimab–cilgavimab for preventing COVID-19 [ID6136]

## Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• AstraZeneca (tixagevimab-cilgavimab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Pulmonary Fibrosis</li> <li>• Addenbrookes Liver Transplant Association</li> <li>• Africa Advocacy Foundation</li> <li>• African Caribbean Leukaemia Trust</li> <li>• African Health Policy Network</li> <li>• Age UK</li> <li>• Allergy UK</li> <li>• Alzheimer’s Society</li> <li>• Anaphylaxis UK</li> <li>• Anthony Nolan</li> <li>• AOFAC Foundation</li> <li>• Aplastic Anaemia Trust</li> <li>• Arthritis and Musculoskeletal Alliance</li> <li>• Asthma and Lung UK</li> <li>• Asthma Relief Charity</li> <li>• BAME Health Collaborative</li> <li>• Beacon</li> <li>• Black Health Agency for Equality</li> <li>• Blood Cancer UK</li> <li>• Blood Pressure UK</li> <li>• British Liver Trust</li> <li>• British Sjögren’s Syndrome Association</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Cardiomyopathy UK</li> <li>• Cardiovascular Care Partnership</li> <li>• Carers Federation</li> <li>• Carers UK</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Chest, Heart and Stroke Scotland</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Diabetes UK Cymru</li> <li>• Healthcare Improvement Scotland</li> <li>• Hospital Information Services - Jehovah's Witnesses</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Northern Ireland Chest, Heart and Stroke Association</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Asthma, Allergy and Inflammation Research Charity</li> <li>• Breathing Matters</li> <li>• British Association for Lung Research</li> <li>• British Society for Cardiovascular</li> </ul>

Final stakeholder list for the Single Technology Appraisal of tixagevimab–cilgavimab for preventing COVID-19 [ID6136]

Issue date: August 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 7

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Chinese National Healthy Living Centre</li> <li>• Chinese Welfare Association</li> <li>• Chronic Lymphocytic Leukaemia Support Association</li> <li>• Chronic Myeloid Leukaemia Support Group</li> <li>• Circulation Foundation</li> <li>• Compassion in Dying</li> <li>• covid:aid</li> <li>• Crohn's &amp; Colitis UK</li> <li>• Cystic Fibrosis Trust</li> <li>• Diabetes Research and Wellness Foundation</li> <li>• Diabetes UK</li> <li>• DKMS</li> <li>• Down's Syndrome Association</li> <li>• Encephalitis Society</li> <li>• Evusheld for the UK</li> <li>• Genetic Alliance UK</li> <li>• GUTS UK</li> <li>• HEART UK</li> <li>• Helen Rollason Cancer Charity</li> <li>• HIV i-Base</li> <li>• Huntington's Disease Association</li> <li>• Immunodeficiency UK</li> <li>• Independent Age</li> <li>• Independent Cancer Patients Voice</li> <li>• InDependent Diabetes Trust</li> <li>• JDRF</li> <li>• Kevin Kararwa Leukaemia Trust</li> <li>• Kidney Care UK</li> <li>• Kidney Research UK</li> <li>• Leukaemia Cancer Society</li> <li>• Leukaemia Care</li> <li>• Liver4Life</li> <li>• Long COVID SOS</li> <li>• Long Covid Support</li> <li>• Lupus UK</li> <li>• Lymphoma Action</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• MDS UK Patient Support Group</li> </ul>	<p>Research</p> <ul style="list-style-type: none"> <li>• Cardiac and Cardiology Research Dept, Barts</li> <li>• Cochrane Acute Respiratory Infections Group</li> <li>• Cochrane Airways Group</li> <li>• Cochrane Haematological Malignancies Group</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Hepato-Biliary Group</li> <li>• Cochrane Infectious Diseases Group</li> <li>• Cochrane Kidney and Transplant Group</li> <li>• Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>• Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group</li> <li>• Cochrane UK</li> <li>• Cochrane Vascular Group</li> <li>• COVID-19 Genomics UK Consortium</li> <li>• David Hide Asthma and Allergy Research Centre</li> <li>• European Council for Cardiovascular Research</li> <li>• Foundation for Liver Research</li> <li>• Genomics England</li> <li>• Health Research Authority</li> <li>• Heart Research UK</li> <li>• Institute for Ageing and Health</li> <li>• Institute of Cancer Research</li> <li>• ISARIC</li> <li>• Kidney Research UK</li> <li>• Leukaemia Busters</li> <li>• Leukaemia UK</li> <li>• Long Covid Research Initiative</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Institute for Health and Care Research</li> <li>• Thrombosis Research Institute</li> <li>• UCL Centre for Sexual Health &amp; HIV Research</li> <li>• Wellcome Sanger Institute</li> <li>• Wellcome Trust</li> </ul>

Final stakeholder list for the Single Technology Appraisal of tixagevimab–cilgavimab for preventing COVID-19 [ID6136]

Issue date: August 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 2 of 7

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Medical Information for Ethnic Minorities</li> <li>• Mencap</li> <li>• Metabolic Support UK</li> <li>• MIND</li> <li>• Motor Neurone Disease Association</li> <li>• MPN Voice</li> <li>• MPS Society</li> <li>• MS Society</li> <li>• MS-UK</li> <li>• Multiple Sclerosis National Therapy Centres</li> <li>• Multiple Sclerosis Trust</li> <li>• Muscular Dystrophy UK</li> <li>• Myeloma UK</li> <li>• NAM</li> <li>• NARA – The Breathing Charity</li> <li>• National AIDS Trust</li> <li>• National Autistic Society</li> <li>• National Kidney Federation</li> <li>• National Rheumatoid Arthritis Society</li> <li>• National Voices</li> <li>• NBTA</li> <li>• Network of Sikh Organisations</li> <li>• Obesity UK</li> <li>• Parkinson’s UK</li> <li>• Patient Safety Learning</li> <li>• PBC Foundation</li> <li>• Polycystic Kidney Disease Charity</li> <li>• Positively UK</li> <li>• Pulmonary Fibrosis Trust</li> <li>• Pumping Marvellous</li> <li>• Race Equality Foundation</li> <li>• Race on the Agenda</li> <li>• Relatives and Residents Association</li> <li>• Sarcoidosis UK</li> <li>• Scleroderma and Raynaud’s UK</li> <li>• Scope</li> <li>• Shine Cancer Support</li> <li>• Sickle Cell Society</li> <li>• SMA UK</li> <li>• Somerville Foundation</li> <li>• South Asian Health Action</li> <li>• South Asian Health Foundation</li> </ul>	<p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Faculty of Public Health</li> <li>• Public Health Wales</li> <li>• Royal Society for Public Health</li> <li>• UK Health Security Agency</li> </ul>

Final stakeholder list for the Single Technology Appraisal of tixagevimab–cilgavimab for preventing COVID-19 [ID6136]

Issue date: August 2022

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• Terrence Higgins Trust</li> <li>• Thrombosis UK</li> <li>• UK-CAB</li> <li>• UK LSD Patient Collaborative Group</li> <li>• UKPIPS</li> <li>• Vasculitis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Respiratory Technology and Physiology</li> <li>• Association for the Study of Obesity</li> <li>• Association of British Clinical Diabetologists</li> <li>• Association of British Neurologists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Clinical Biochemists - Microbiology Section</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• British Association for Nursing in Cardiovascular Care</li> <li>• British Association for Sexual Health and HIV</li> <li>• British Association for the Study of the Liver (BASL)</li> <li>• British Association of Endocrine and Thyroid Surgeons</li> <li>• British Association of Urological Nurses</li> <li>• British Cardiovascular Society</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British HIV Association</li> <li>• British Infection Association</li> <li>• British Nuclear Cardiology Society</li> <li>• British Pharmacological Society</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Allergy and Clinical Immunology</li> <li>• British Society for Haematology</li> </ul>	

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• British Society for Haemostasis and Thrombosis</li> <li>• British Society for Heart Failure</li> <li>• British Society for Immunology</li> <li>• British Society for Rheumatology</li> <li>• British Society of Blood and Marrow Transplantation and Cellular Therapy</li> <li>• British Thoracic Society</li> <li>• British Transplantation Society</li> <li>• Cancer Research UK</li> <li>• Clinical Leaders of Thrombosis</li> <li>• Encephalitis Society</li> <li>• Faculty of Pharmaceutical Medicine</li> <li>• ILD-IN: Interstitial Lung Diseases Interdisciplinary Network</li> <li>• Immunology and Allergy Nursing Group</li> <li>• Infection Prevention Society</li> <li>• National Clinical Expert group for Immunocompromised</li> <li>• National Heart and Lung Institute</li> <li>• NHS Blood and Transplant</li> <li>• Primary Care Diabetes Society</li> <li>• Primary Care Respiratory Society UK</li> <li>• Primary Care Rheumatology and Musculoskeletal Medicine Society</li> <li>• Rheumatoid Arthritis Surgical Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of Emergency Medicine</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science and Technology</li> <li>• Society for DGH Nephrologists</li> <li>• Society for Endocrinology</li> <li>• Society for General Microbiology</li> <li>• Society of Vascular Nurses</li> <li>• Therapists in MS</li> <li>• TREND UK</li> <li>• UK Clinical Pharmacy Association</li> </ul>	

Final stakeholder list for the Single Technology Appraisal of tixagevimab–cilgavimab for preventing COVID-19 [ID6136]

Issue date: August 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 5 of 7

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• UK Clinical Virology Network</li> <li>• UK CLL Forum</li> <li>• UK Cystic Fibrosis Medical Association</li> <li>• UK Kidney Association</li> <li>• UK Multiple Sclerosis Specialist Nurses Association</li> <li>• UK Oncology Nursing Society</li> <li>• UK Primary Immunodeficiency Network</li> <li>• UK Renal Pharmacy Group</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.